[O26-1] O26-1: Immunosuppressive drugs: assay and genotyping
Chairs: Stein Bergan, Norway / Maria Shipkova, Germany
Tue. Sep 26, 2017 10:30 AM - 11:15 AM  Room C1  (1F)

(O26-1-1] Assessment of automated electrochemiluminescence immunoassay for everolimus
Kimitaka Suetsugu¹, Nanae Yamamoto², Yuichi Tsuchiya³, Kumi Matsukawa⁴, Tomohiro Shigematsu⁵, Nobuaki Egashira⁶, Satohiro Masuda⁷ (1.Kyushu University Hospital, 2.Kyushu University Hospital, 3.Kyushu University Hospital, 4.Kyushu University Hospital, 5.Kyushu University Hospital, 6.Kyushu University Hospital, 7.Kyushu University Hospital)
Keywords: everolimus, therapeutic drug monitoring, ECLIA, immunoassay

Background
Therapeutic drug monitoring (TDM) of everolimus is essential to maintain the safety and efficacy in personalized immunosuppressive therapy. Several methodologies to measure the blood levels of everolimus are available. This study was to evaluate a new automated electrochemiluminescence immunoassay (ECLIA, Roche Diagnostics, Co. Ltd.) for measuring blood concentrations of everolimus in clinical practice.

Methods
Spiked whole blood samples were used to evaluate performance of ECLIA (linearity, lower limit of quantification, within-run and intermediate imprecision). Residual EDTA whole blood concentrations of everolimus in transplant patients were measured by ECLIA, latex agglutination (LA, Sekisui Medical, Co. Ltd.) (n = 116), and liquid chromatography with tandem mass spectrometry (LC-MS/MS, AB Sciex, Co. Ltd.) (n = 126). Characteristics of blood concentration measurement system on everolimus were shown in Table 1. In addition, we examined whether simultaneous measurement of everolimus and tacrolimus was available or not using residual EDTA whole blood samples (n = 51).

Results
Linearity from 0.5 to 30 ng/mL was observed, and lower limitation of quantification of 0.22 ng/mL at 20% coefficient of variation was determined. Imprecision testing gave coefficients of variation less than 6% for both within-run and intermediate imprecision. Values obtained with the ECLIA were highly correlated with the LA (ECLIA= 0.98× LA + 1.25; r=0.96), and with the LC-MS/MS (ECLIA=1.13× LC-MS/MS + 0.99; r=0.95). A good correlation between simultaneous measurement and independent measurement was observed for everolimus and tacrolimus, respectively (r > 0.99).

Conclusions
The ECLIA is a sensitive and useful method for routine TDM of everolimus.

Table1. Characteristic of blood concentration measurement system on everolimus
Zoom image